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Fig. 1. Cholangiocarcinoma with (A) vascular invasion and (B) non-tumoral
peripheral tissues with cholangitis.
Letters to the EditorTo the Editor:
Multidrug resistance protein 3 (MDR3), also known as ATP-bind-
ing cassette subfamily B, member 4 (ABCB4), is predominantly
expressed in the liver and is the critical translocator for phospho-
lipids across canalicular membranes of hepatocytes [1,2]. MDR3
mutations are responsible for progressive familial intrahepatic
cholestasis type 3 (PFIC3), low phospholipid-associated choleli-
thiasis (LPAC syndrome) and intrahepatic cholestasis of preg-
nancy (ICP) [3]. Cholangiocarcinoma (CCa) is a rare malignant
tumour of the biliary tract, characterized by a dramatically poor
prognosis usually due to a delayed diagnosis and inefﬁcient
non-surgical treatments [4]. To our knowledge, up to now no
association between CCa and MDR3 mutations has been reported.
In this letter to the editor, we report two cases of association
between MDR3 gene mutations and CCa in two non-related
families.
In the ﬁrst family, patient 1, a 53-year-old man, was investi-
gated for a perihilar tumoral obstruction and treated by right
hepatic lobectomy. The pathological examination showed a CCa
with one lymph node metastasis. Non-tumoral peripheral tissues
showed signs of cholangitis and ductopenia (Fig. 1). After surgery,
itching persisted, alkaline phosphatase level was 894 UI/L and
MRI showed multiple partial stenosis of the remaining biliary
tract. The patient was given ursodeoxycholic acid (UDCA) with
a marked decrease in alkaline phosphatase to 258 UI/L. Twenty-
six months after surgery, the CCa recurred with peritoneal carci-
nosis and the patient died 13 months after the diagnosis of CCa
recurrence. Patient 2, patient 1’s daughter, had a cholecystectomy
at 14 years old for symptomatic gallstones. At 23 years old, she
presented with jaundice and itching, which resolved spontane-
ously. A MDR3 familial biliary disease was suspected. The mis-
sense variation NM_000443.3: c.1469T>C in exon 13 was found
with heterozygous status in the liver tissue of patient 1 and in
the blood leucocytes of patient 2. This heterozygous variation
leads to NP_000434: p.Ile490Thr at MDR3 protein level. It is a
new variant, but according to SIFT software specialized in muta-
tion interpretation, it predicts a non-functional protein.
In the second family, a 55-year-old woman (patient 3), was
treated by right hepatectomy for a large perihilar CCa. The path-
ological examination revealed major ductopenia and inﬂamma-
tory biliary ducts in the non-tumoral peripheral liver tissue.
Ten months after the surgery, a recurrence was detected by CT
scan and the patient died 31 months after the initial surgery.
Patient 4, patient 3’s sister, a 38-year-old woman, had a cholecys-
tectomy at 20 years old for gallstones and surgical ablation of
residual gallstones in the common bile duct at 24 years old. She
also had an ICP during her ﬁrst pregnancy. A resection of the right
liver was decided due to post-operative common bile duct steno-
sis and intrahepatic gallstones in segments V and VIII. Histologi-
cal analysis showed biliary duct inﬂammation and liver ﬁbrosis
probably subsequent to chronic cholestasis. After surgery, she
still presented with pruritus, elevated liver enzymes (alkaline
phosphatase at 300 IU/L) and developed signs of portal hyperten-Journal of Hepatology 2sion due to liver ﬁbrosis. Due to intrahepatic lithiasis suggesting
LPAC syndrome, we carried out research in order to ﬁnd the
MDR3 mutation. A heterozygous missense sequence variation in
exon 24, NM_000443.3:c.2932T>C leading to NP_ 000434:
pSer978Pro at the MDR3 protein level was found. Using her par-
afﬁn-embedded hepatic tissue, we found the same MDR3 variant
in her sister (patient 3), at heterozygous status. The mutation has
already been encountered in ﬁve other families in France.
Cholangiocarcinomas represent less than 5% of digestive
tumours and commonly identiﬁed risk factors are primary scle-
rosing cholangitis, congenital biliary abnormalities and hepatoli-
thiasis [5]. Nevertheless, they represent only a minority of CCa
cases. Neither genomic mutation nor hereditary predisposition
has been found to be associated with the development of CCa.
Cases of intrahepatic CCa from pediatric patients affected by
the homozygous mutations of BSEP (Bile Salt Export Pomp), the
main bile acid transporter in hepatocytes, have been reported
[6]. The CCa mechanisms associated during the process with BSEP
and MDR3 mutations are probably the same, but have yet to be
satisfactorily explained. It is well-known that inactive MDR3 is
responsible for the accumulation of altered bile in hepatocytes
and cholangiocytes, thereby causing microscopic forms of liver
damage such as inﬂammation and ﬁbrosis [7]. Chronic biliary
inﬂammation can increase cholangiocyte turnover, thereby012 vol. 57 j 467–477
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enhancing the growth of altered cholangiocytes and leading to
increased CCa susceptibility [8,9].
These case reports suggest a need for prospective follow-up of
patients withMDR3mutations, in order to identify the CCa risk. It
would probably also be interesting to look for an MDR3 mutation
in young patients with CCa, especially if there exists a familial
history of CCa or biliary disease.Conﬂict of interest
The authors declared that they do not have anything to disclose
regarding funding or conﬂict of interest with respect to this
manuscript.
Acknowledgements
The authors thank Jeffrey Arsham for editing the manuscript.
The authors thank Valerie Paradis, Dominique Valla, Jacques Belg-
hiti and Christine Silvain for their contributions to this work.
References
[1] van Helvoort A, Smith AJ, Sprong H, Fritzsche I, Schinkel AH, Borst P, et al.
MDR1 P-glycoprotein is a lipid translocase of broad speciﬁcity, while MDR3 P-
glycoprotein speciﬁcally translocates phosphatidylcholine. Cell
1996;87:507–517.
[2] Davit-Spraul A, Gonzales E, Baussan C, Jacquemin E. The spectrum of liver
diseases related to ABCB4 gene mutations: pathophysiology and clinical
aspects. Semin Liver Dis 2010;30:134–146.
[3] Jacquemin E. Role of multidrug resistance 3 deﬁciency in pediatric and adult
liver disease: one gene for three diseases. Semin Liver Dis 2001;21:551–562.
[4] Tyson GL, El-Serag HB. Risk factors of cholangiocarcinoma. Hepatology
2011;54:173–184.
[5] Cardinale V, Semeraro R, Torrice A, Gatto M, Napoli C, Bragazzi MC, et al.
Intra-hepatic and extra-hepatic cholangiocarcinoma: new insight into epide-
miology and risk factors. World J Gastrointest Oncol 2010;2:407–416.
2008;14:2986–2989.
[9] Jaiswal M, LaRusso NF, Burgart LJ, Gores GJ. Inﬂammatory cytokines induce
DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric
oxide-dependent mechanism. Cancer Res 2000;60:184–190.
David Tougeron⇑
Department of Hepatology and Gastroenterology,
Poitiers University Hospital, Poitiers, France
Laboratoire Inﬂammation Tissus Epithéliaux et Cytokines,
EA 4331, University of Poitiers, Poitiers, France⇑Corresponding author. Address: Department of Hepatology and
Gastroenterology, Poitiers University Hospital, 2 rue de la Milétrie,
86000 Poitiers Cedex, France
Tel.: +33 5 49 44 37 51; fax: +33 5 49 44 38 35
E-mail address: davidtougeron@hotmail.fr
Ginette Fotsing
Department of Hepatology and Gastroenterology,
Poitiers University Hospital, Poitiers, France
Veronique Barbu
AP-HP, LCBGM, Saint-Antoine Hospital, UPMC Univ Paris 06 &
INSERM, UMR_S 938, CdR Saint-Antoine, Paris, France
Michel Beauchant
Department of Hepatology and Gastroenterology,
Poitiers University Hospital, Poitiers, France
The optimal dose of omega-3 supplementation for non-alcoholic
fatty liver diseaseTo the Editor:
Non-alcoholic fatty liver disease (NAFLD) is a burgeoning health
problem that affects one-third of adults and an increasing num-
ber of children in developed countries [1]. It was previously
reported that various therapeutic regimens can be adopted for
NAFLD [2], including weight loss agents, bariatric surgery, insu-
lin-sensitizing agents, lipid-lowering agents, antioxidants, and
other novel compounds. However, there is no consensus on its
treatment. Both lifestyle therapy and pharmacotherapy have lim-
itations due to poor compliance and side effects. Therefore, new
therapeutic approaches to managing NAFLD are urgently needed.
We read with interest the study by Parker et al. [3]. This is the
ﬁrst meta-analysis to investigate the effect of omega-3 polyunsat-
urated fatty acid (PUFA) on liver fat in humans. The authors found
that omega-3 PUFA could decrease liver fat and that beneﬁts were
seen with a consumption of >0.83 g/day. The results are instruc-
tive for the therapeutic regimen of NAFLD; however, we have
some concerns over the optimal dose mentioned in the article.468 Journal of Hepatology 20Given the complications of NAFLD, especially cardiovascular
disease (CVD), the optimal dose of omega-3 PUFA should be
much higher than 0.83 g/day. Targher et al. revealed a strong
association between NAFLD and CVD risk by reviewing accumu-
lating clinical evidence [4]. Previous evidence suggests that CVD
dictates the outcome in patients with NAFLD more frequently
and to a greater extent than does the progression of liver disease,
and CVD is the most important cause of death in NAFLD patients
[5]. On the other hand, many investigators have demonstrated
that omega-3 PUFA could prevent CVD [6]. In a large-scale inter-
vention trial of secondary prevention after myocardial infarction,
GISSI-Prevenzione investigators identiﬁed a substantial reduction
in all-cause and cardiovascular mortality with 1 g per day of n-3
PUFA supplementation [7]. In addition, McKenney et al. recom-
mend n-3 PUFA supplementation at a dose of 2–4 g per day to
patients with high triglyceride concentrations [8]. At present,
Saravanan et al. found that omega-3 PUFA could act as beneﬁcial
pleiotropic agents to prevent CVD, by conducting a review of
numerous clinical trials [9]. As ﬁsh is rich in omega-3 PUFA, the12 vol. 57 j 467–477
